Annovis Bio Partners With Weave Bio to Use AI in Buntanetap NDA Submission

Annovis Bio Inc. (ANVS) announced on September 23, 2026, a partnership with Weave Bio to use artificial intelligence in advancing its lead candidate buntanetap toward a New Drug Application (NDA). The clinical-stage biotechnology company said the collaboration is intended to support the regulatory submission process for buntanetap. Financial terms of the agreement were not disclosed. Annovis Bio focuses on developing therapies for neurodegenerative diseases. The company did not specify a timeline for the NDA filing.